Skip to main content
. 2021 Mar 11;9:630712. doi: 10.3389/fcell.2021.630712

FIGURE 5.

FIGURE 5

Combination of SHP099 with other drugs enhances antitumor efficacy. In patient-derived xenograft (PDX) mouse model, temozolomide (TMZ) combines with SHP099 to increase the survival rate of tumor-carrying mice. The combination of SHP099 with MEK inhibitor, Erk inhibitor, ALK inhibitor, or sorafenib impairs the survival of malignancies, which indicates that the drug toxicity is enhanced through the drug combination.